Clinical trial
Efficacy Study of IL-21 to Treat Metastatic Melanoma
NCT00336986 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00336986 |
|---|---|
| Title | Efficacy Study of IL-21 to Treat Metastatic Melanoma |
| Official title | An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Malignant Melanoma |
| Intervention type | Drug |
| Interventions | recombinant interleukin-21 |
| Enrollment | 54 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jun 15, 2006 |
| Last update posted | Aug 14, 2023 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: